1
|
Dorn GW II: Novel pharmacotherapies to
abrogate postinfarction ventricular remodeling. Nat Rev Cardiol.
6:283–291. 2009.
|
2
|
Deboer MD: The use of ghrelin and ghrelin
receptor agonists as a treatment for animal models of disease:
efficacy and mechanism. Curr Pharm Des. 18:4779–4799. 2012.
|
3
|
Strasser F: Clinical application of
ghrelin. Curr Pharm Des. 18:4800–4812. 2012.
|
4
|
Kojima M, Hosoda H, Date Y, et al: Ghrelin
is a growth-hormone-releasing acylated peptide from stomach.
Nature. 402:656–660. 1999.
|
5
|
Isgaard J: Ghrelin and the cardiovascular
system. Endocr Dev. 25:83–90. 2013.
|
6
|
Baatar D, Patel K and Taub DD: The effects
of ghrelin on inflammation and the immune system. Mol Cell
Endocrinol. 340:44–58. 2011.
|
7
|
Repaci A, Gambineri A, Pagotto U and
Pasquali R: Ghrelin and reproductive disorders. Mol Cell
Endocrinol. 340:70–79. 2011.
|
8
|
Yang J, Liu GQ, Wei R, et al: Ghrelin
promotes differentiation of human embryonic stem cells into
cardiomyocytes. Acta Pharmacol Sin. 32:1239–1245. 2011.
|
9
|
Huang CX, Yuan MJ, Huang H, et al: Ghrelin
inhibits post-infarct myocardial remodeling and improves cardiac
function through anti-inflammation effect. Peptides. 30:2286–2291.
2009.
|
10
|
Kishimoto I, Tokudome T, Hosoda H, et al:
Ghrelin and cardiovascular diseases. J Cardiol. 59:8–13. 2012.
|
11
|
Xu X, Ding F, Pang J, et al: Chronic
administration of hexarelin attenuates cardiac fibrosis in the
spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol.
303:H703–H711. 2012.
|
12
|
Mao Y, Tokudome T, Otani K, et al: Ghrelin
prevents incidence of malignant arrhythmia after acute myocardial
infarction through vagal afferent nerves. Endocrinology.
153:3426–3434. 2012.
|
13
|
Yuan MJ, Huang CX, Tang YH, et al: A novel
peptide ghrelin inhibits neural remodeling after myocardial
infarction in rats. Eur J Pharmacol. 618:52–57. 2009.
|
14
|
Gnanapavan S, Kola B, Bustin SA, et al:
The tissue distribution of the mRNA of ghrelin and subtypes of its
receptor, GHS-R, in humans. J Clin Endocrinol Metabol.
87:29882002.
|
15
|
Gaytan F, Barreiro ML, Caminos JE, et al:
Expression of ghrelin and its functional receptor, the type 1a
growth hormone secretagogue receptor, in normal human testis and
testicular tumors. J Clin Endocrinol Metab. 89:400–409. 2004.
|
16
|
Ghelardoni S, Carnicelli V, Frascarelli S,
et al: Ghrelin tissue distribution: comparison between gene and
protein expression. J Endocrinol Invest. 29:115–121. 2006.
|
17
|
Iglesias MJ, Pineiro R, Blanco M, et al:
Growth hormone releasing peptide (ghrelin) is synthesized and
secreted by cardiomyocytes. Cardiovasc Res. 62:481–488. 2004.
|
18
|
Nishi Y, Yoh J, Hiejima H and Kojima M:
Structures and molecular forms of the ghrelin-family peptides.
Peptides. 32:2175–2182. 2011.
|
19
|
Chen C, Wu D and Clarke IJ: Signal
transduction systems employed by synthetic GH-releasing peptides in
somatotrophs. J Endocrinol. 148:381–386. 1996.
|
20
|
Lodeiro M, Theodoropoulou M, Pardo M, et
al: c-Src regulates Akt signaling in response to ghrelin via
beta-arrestin signaling-independent and -dependent mechanisms. PLoS
One. 4:e46862009.
|
21
|
Camiña JP, Lodeiro M, Ischenko O, et al:
Stimulation by ghrelin of p42/p44 mitogen-activated protein kinase
through the GHS-R1a receptor: role of G-proteins and
beta-arrestins. J Cell Physiol. 213:187–200. 2007.
|
22
|
Wang Y, Narsinh K, Zhao L, et al: Effects
and mechanisms of ghrelin on cardiac microvascular endothelial
cells in rats. Cell Biol Int. 35:135–140. 2011.
|
23
|
Chen JH, Huang SM, Chen CC, et al: Ghrelin
induces cell migration through GHS-R, CaMKII, AMPK, and NF-κB
signaling pathway in glioma cells. J Cell Biochem. 112:2931–2941.
2011.
|
24
|
Holliday ND, Holst B, Rodionova EA, et al:
Importance of constitutive activity and arrestin-independent
mechanisms for intracellular trafficking of the ghrelin receptor.
Mol Endocrinol. 21:3100–3112. 2007.
|
25
|
Iantorno M, Chen H, Kim JA, et al: Ghrelin
has novel vascular actions that mimic PI 3-kinase-dependent actions
of insulin to stimulate production of NO from endothelial cells. Am
J Physiol Endocrinol Metab. 292:E756–E764. 2007.
|
26
|
Xu X, Jhun BS, Ha CH and Jin ZG: Molecular
mechanisms of ghrelin-mediated endothelial nitric oxide synthase
activation. Endocrinology. 149:4183–4192. 2008.
|
27
|
Chen X, Chen Q, Wang L and Li G: Ghrelin
induces cell migration through GHSR1a-mediated PI3K/Akt/eNOS/NO
signaling pathway in endothelial progenitor cells. Metabolism.
62:743–752. 2013.
|
28
|
Lacerda-Miranda G, Soares VM, Vieira AK,
et al: Ghrelin signaling in heart remodeling of adult obese mice.
Peptides. 35:65–73. 2012.
|
29
|
Ma Y, Zhang L, Edwards JN, et al: Growth
hormone secretagogues protect mouse cardiomyocytes from in vitro
ischemia/reperfusion injury through regulation of intracellular
calcium. PLoS One. 7:e352652012.
|
30
|
Kanashiro-Takeuchi RM, Takeuchi LM, Rick
FG, et al: Activation of growth hormone releasing hormone (GHRH)
receptor stimulates cardiac reverse remodeling after myocardial
infarction (MI). Proc Natl Acad Sci USA. 109:559–563. 2012.
|
31
|
Kanashiro-Takeuchi RM, Tziomalos K,
Takeuchi LM, et al: Cardioprotective effects of growth
hormone-releasing hormone agonist after myocardial infarction. Proc
Natl Acad Sci USA. 107:2604–2609. 2010.
|
32
|
Casanueva FF, Camina JP, Carreira MC, et
al: Growth hormone-releasing hormone as an agonist of the ghrelin
receptor GHS-R1a. Proc Natl Acad Sci USA. 105:20452–20457.
2008.
|
33
|
Beiras-Fernandez A, Kreth S, Weis F, et
al: Altered myocardial expression of ghrelin and its receptor
(GHSR-1a) in patients with severe heart failure. Peptides.
31:2222–2228. 2010.
|
34
|
Buss SJ, Riffel JH, Malekar P, et al:
Chronic Akt blockade aggravates pathological hypertrophy and
inhibits physiological hypertrophy. Am J Physiol Heart Circ
Physiol. 302:H420–H430. 2012.
|
35
|
Chen LL, Zhu TB, Yin H, et al: Inhibition
of MAPK signaling by eNOS gene transfer improves ventricular
remodeling after myocardial infarction through reduction of
inflammation. Mol Biol Rep. 37:3067–3072. 2010.
|